南新制藥(688189.SH):擬掛牌轉讓常德臻誠100%股權
格隆匯11月15日丨南新制藥(688189.SH)公佈,鑑於公司的全資子公司常德臻誠業務持續虧損,根據公司的整體經營規劃和業務結構,結合行業發展情況,為進一步優化公司的管理架構、降低管理成本,提高整體運營效率,妥善處置不良資產,公司擬通過湖南聯交所公開掛牌轉讓公司的全資子公司常德臻誠100%股權。公司董事會提請股東大會授權公司總經理或總經理指定的授權代理人負責實施相關工作,包括但不限於辦理在湖南聯交所公開掛牌轉讓手續、與交易對方進行具體洽談並簽署相關協議等。
公司本次對外轉讓全資子公司常德臻誠100%股權,有利於優化公司資源配置,提高整體運營效率,降低運營成本,聚焦公司主業,提升公司綜合實力,符合公司的整體發展戰略。本次交易完成後,常德臻誠將不再納入公司合併報表範圍。本次交易不會影響公司的正常生產經營,對公司損益產生的影響以最終成交結果為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.